ClinicalTrials.gg
CompletedNCT00424333Updated Feb 13, 2007

Six Month Clinical Trial Assessing Efficacy and Safety of Inhaled Insulin in Type 1 Diabetes

A Phase 3 interventional study of Inhaled human insulin in Diabetes Mellitus, Type 1, sponsored by Pfizer. Completed at 35 sites in 2 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2007-02-13.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.

Enrollment
8th of 35
320 · median 74
Started
1999
with 1 other
Phase 3
17 of 35
none open now
Registered
9th of 35
by date
Lead sponsor
2 of 35
Pfizer

Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 8th largest by enrollment, is one of 2 that started in 1999, is one of 17 in phase 3, and was the 9th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

To determine in subjects with Type 1 Diabetes Mellitus:

  1. Whether glycemic control can be achieved at least as effectively with a) an intensive insulin regimen involving pre-meal inhaled insulin plus twice daily subcutaneous NPH insulin as with b) an intensive subcutaneous insulin regimen involving pre-meal regular insulin plus twice daily NPH, given as 4 injections per day. The treatment regimens differ only by the route of delivery of the short acting insulin.
  2. The toleration and safety of inhaled insulin therapy and its effects after 6months, if any, on measures of pulmonary function.
03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 Diabetes for more than 1 year
  • Stable insulin regimen of at least 2 injections per day

Exclusion criteria

Exclusion Criteria:

  • Any smoking within the last 6 months. Smoking is not permitted at any time during this study.
  • Subjects on insulin pump during 2 months prior to screening.
  • Subjects with poorly-controlled asthma, , or other significant respiratory disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Primary outcome is 24 week change in baseline in HbA1c.

Secondary outcomes

  1. The secondary endpoints include the following efficacy assessments:

  2. Incidence of hypoglycemia

  3. Proportion of subjects with acceptable glycemic control (e.g., HbA1c<8%)

  4. Change from baseline in fasting lipid profile

  5. Change from baseline in fasting plasma glucose level

  6. Change from baseline in meal glucose response (2-hour postprandial increment in plasma glucose)

  7. Dose of insulin (total dose of injected sustained-duration insulin, and total dose of inhaled or injected Regular insulin during the study).

  8. Change from baseline in body weight

  9. Change from baseline in 24-hour home glucose profile (based on the area under the glucose profile curve calculated by the trapezoid rule with special weights assigned to the pre-breakfast and bedtime assessments).

  10. Patient satisfaction and preference.

07

Study locations

35 sites
  • Pfizer Investigational Site
    Duarte, California, United States
  • Pfizer Investigational Site
    Long Beach, California, United States
  • Pfizer Investigational Site
    Los Angeles, California, United States
  • Pfizer Investigational Site
    Stanford, California, United States
  • Pfizer Investigational Site
    Denver, Colorado, United States
  • Pfizer Investigational Site
    New Haven, Connecticut, United States
  • Pfizer Investigational Site
    Gainesville, Florida, United States
  • Pfizer Investigational Site
    Hollywood, Florida, United States
  • Pfizer Investigational Site
    Miami, Florida, United States
  • Pfizer Investigational Site
    Tallahassee, Florida, United States
  • Pfizer Investigational Site
    Peoria, Illinois, United States
  • Pfizer Investigational Site
    Skokie, Illinois, United States
  • Pfizer Investigational Site
    Lutherville, Maryland, United States
  • Pfizer Investigational Site
    Waltham, Massachusetts, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota, United States
  • Pfizer Investigational Site
    Columbia, Missouri, United States
  • Pfizer Investigational Site
    Bronx, New York, United States
  • Pfizer Investigational Site
    New Hyde Park, New York, United States
  • Pfizer Investigational Site
    Rochester, New York, United States
  • Pfizer Investigational Site
    Syracuse, New York, United States
  • Pfizer Investigational Site
    Durham, North Carolina, United States
  • Pfizer Investigational Site
    Winston-salem, North Carolina, United States
  • Pfizer Investigational Site
    Portland, Oregon, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania, United States
  • Pfizer Investigational Site
    Dallas, Texas, United States
  • Pfizer Investigational Site
    Houston, Texas, United States
  • Pfizer Investigational Site
    Burlington, Vermont, United States
  • Pfizer Investigational Site
    Charlottesville, Virginia, United States
  • Pfizer Investigational Site
    Charlottsville, Virginia, United States
  • Pfizer Investigational Site
    Seattle, Washington, United States
  • Pfizer Investigational Site
    Edmonton, Alberta, Canada
  • Pfizer Investigational Site
    Hamilton, Ontario, Canada
  • Pfizer Investigational Site
    Mississauga, Ontario, Canada
  • Pfizer Investigational Site
    Toronto, Ontario, Canada
  • Pfizer Investigational Site
    Montreal, Quebec, Canada
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 1999 and a completion of Oct 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2007
First posted
Jan 19, 2007
Start
May 1999
Completion
Oct 2000
Last update
Feb 13, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Feb 13, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00424333
Lead sponsor
Pfizer
First posted
Jan 19, 2007
Start date
May 1999
Completion
Oct 2000
Last update
Feb 13, 2007

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion